NCT07187661Completed
Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis
Efficacy of Intra-Articular Bevacizumab in Preventing Recurrent Hemarthrosis in Hemophilia Patients With Chronic Synovitis: A Pre- and Post-Design Study
Source: ClinicalTrials.gov · Last updated 25 Jun 2026
Brief summary (registry, in English)
Hemophilia is an inherited bleeding disorder characterized by deficiency of clotting factors, leading to increased bleeding tendencies. The most common complications are joint bleeds (hemarthroses), which cause chronic changes in joints and ultimately disability. Recurrent hemarthroses often result from chronic synovitis in target joints of patients with hemophilia, a process driven by Vascular Endothelial Growth Factor (VEGF) mediated pathological angiogenesis. Intra-articular administration of Bevacizumab, a VEGF neutralizing monoclonal antibody, may block this process and reduce the frequency of recurrent joint bleeds. This study evaluates the efficacy and safety of intra-articular Bevacizumab for preventing recurrent hemarthrosis in patients with hemophilia and chronic synovitis.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 10 Sept 2025
- Start date
- 9 Sept 2025
- Primary completion date
- 28 Mar 2026
- Lead sponsor
- Khyber Medical University Peshawar
- Diseases
- Haemophilia
- NCT number
- NCT07187661
What you commit to
- Study type: Interventional
- Participants enrolled: 18
- From 9 Sept 2025 to the primary completion date, 28 Mar 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent major surgery/trauma (\<28 days).
Other illness
- HIV positive diagnosis.
- Uncontrolled hypertension.
- Serious non-healing wound, active cardiovascular disease, or other significant comorbidities that could increase risk or interfere with the study.
Other
- Severely damaged joints or anatomical limitations preventing safe injection.
- Contraindications to MRI.
Who the study is looking for
- Confirmed diagnosis of Hemophilia A.
- Presence of one or more target joints (knee, elbow, ankle) with chronic synovitis and a history of \>2 hemarthrosis episodes in the past 6 months.
- Target joint World Federation of Hemophilia (WFH) joint score of 2-3.
- Adequate hematological, renal, and liver function (as specified by protocol lab values).
- Ability and willingness to provide informed consent and comply with the study protocol.
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Pathology and Diagnostic Medicine (IPDM) Coordinator of this site? Confirm its status | Peshawar | Pakistan | Unknown status |
| Hayatabad Medical Complex Coordinator of this site? Confirm its status | Peshawar | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.